Sorafenib in Myelodysplastic Syndrome

This study has been terminated.
(Early closure of study due to poor response)
Sponsor:
Collaborator:
Bayer
Information provided by (Responsible Party):
Duke University
ClinicalTrials.gov Identifier:
NCT00510289
First received: July 30, 2007
Last updated: December 20, 2013
Last verified: December 2013
  Purpose

The purpose of this study is to evaluate the efficacy of sorafenib in patients with Myelodysplastic Syndrome (MDS). Eligible subjects will receive Sorafenib administered at 400mg orally twice a day, given on days 1-28 of a 28-day cycle. Patients will be evaluated for hematological response after 2 cycles and then every 3 cycles thereafter for a maximum of 5 years from study entry. If a patient achieves a complete response they may receive an additional 6 cycles of therapy beyond documentation of complete response unless unacceptable toxicity occurs. For patients with partial response, hematological improvement or stable disease they will continue treatment until relapse, progression of disease, or unacceptable toxicity occurs.


Condition Intervention Phase
Myelodysplastic Syndromes
Leukemia, Myelomonocytic, Chronic
Drug: Sorafenib
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Trial of Sorafenib in Patients With Myelodysplastic Syndrome

Resource links provided by NLM:


Further study details as provided by Duke University:

Primary Outcome Measures:
  • Number of Subjects Achieving Hematological Response [ Time Frame: During treatment - up to a maximum of 5 years ] [ Designated as safety issue: No ]
    Hematological response is defined as the number of subjects who achieve either a complete response (CR), Partial response (PR) or Hematologic improvement.(HI). HI is defined as peripheral blood counts with hemoglobin ≥11 g/dL, absolute neutrophil count ≥1x10(9)/L and platelet count ≥100x10(9)/L, and normal bone marrow morphology with no evidence of dysplasia or blasts. CR is defined as the disappearance of all signs and symptoms related to disease, along with HI. PR is defined as fulfilling the criteria for CR in the peripheral blood but blasts decreasing by 50% or more in the bone marrow or to a less advanced WHO classification pretreatment.


Secondary Outcome Measures:
  • Number of Subjects Requiring Dose Reductions [ Time Frame: While on study drug, a maximum of 5 years ] [ Designated as safety issue: Yes ]
    The number of subjects who took study drug for more than 1 cycle and required a dose reduction down to the next dose level.

  • Time to Progression [ Time Frame: 5 years ] [ Designated as safety issue: No ]
    Time to progression will be defined as the number of months between on-study and the date of progression or death, whichever comes first, in subjects who took study drug for at least cycle 1.

  • Overall Survival [ Time Frame: 1 year from the last dose of study drug ] [ Designated as safety issue: No ]
    Overall Survival is defined as the number of months from enrollment onto the study until death from any cause in subjects who took study drug for at least cycle 1.

  • Change in Microvessel Density [ Time Frame: Measured before and after treatment ] [ Designated as safety issue: No ]
    Microvessel density will be measured before and after treatment, and the distribution of change across time will be summarized with descriptive statistics.


Enrollment: 19
Study Start Date: July 2006
Study Completion Date: July 2011
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: all patients
sorafenib
Drug: Sorafenib
400 mg twice a day until progression or unacceptable toxicity develops.
Other Name: Nexavar

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have a diagnosis of primary or therapy-related myelodysplastic syndrome or myelodysplastic/ myeloproliferative disorders as defined by the WHO

    • Refractory anemia with excess blasts - 1 or 2
    • Chronic myelomonocytic leukemia type 2
    • Refractory anemia, refractory anemia with ringed sideroblasts, refractory cytopenia with multilineage dysplasia, refractory cytopenia with multilineage dysplasia with ringed sideroblasts, 5q- syndrome, myelodysplastic syndrome unclassified or chronic myelomonocytic leukemia type 1 if at least one of the following criteria is met: HgB < 10 g/dl, Platelets < 50,000/ul,ANC < 1,000 ul, Transfusion dependent defined as 2 transfusions within an 8 week period.
  • Patients may have low, intermediate-1, intermediate-2 or high risk MDS or CMML.
  • Patients are eligible without regard to prior treatment status except for allogenic bone marrow transplant.
  • Patients must be 18 years of age or older.
  • Patient has an estimated or measured creatinine clearance ≥30 ml/min at study enrollment.
  • AST, ALT, total bilirubin ≤ than 2.5 times the upper limit of normal.
  • ECOG performance status of 0-2.
  • Voluntary written informed consent before performance of any study-related procedure not part of normal medical care.
  • Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control.
  • Male subject agrees to use an acceptable method for contraception for the duration of the study therapy and for 2 weeks after study completion.

Exclusion Criteria:

  • Female subject is pregnant or lactating. Confirmation that the subject is not pregnant must be established by a negative serum B-human chorionic gonadotropin (B-hCG) pregnancy test result within 2 weeks of enrollment. Pregnancy testing is not required for post-menopausal or surgically sterilized women.
  • Patient has received other investigational drugs for this disease within 14 days of enrollment
  • No growth factor support with erythropoietin, GCSF, or GMCSF within 28 days of enrolling in the study.
  • Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
  • Patients with another malignancy within the last one year (from documentation of remission) other than basal or squamous cell skin cancer or CIS of the cervix.
  • Patients who underwent allogeneic stem cell transplant will be excluded.
  • History of leukemia (having more than 20% blasts in blood or marrow)
  • Current treatment with coumadin, heparin and its derivatives.
  • Major surgery (including needle biopsy of visceral organs) for 1-month prior to study and fully recovered. In addition, no placement of a subcutaneous or tunneled venous access device for 3 days prior to study and adequately healed.
  • Significant cardiac or vascular events within 6 months: acute MI, unstable angina, severe peripheral vascular disease (ischemic pain at rest class 3 or worse, non-healing ulcers/wounds, congestive heart failure (NHYA class ≥ 2), uncontrolled cardiac arrhythmias, and disseminated intravascular coagulation.
  • No use of hematopoetic growth factors within 4 weeks of starting sorafenib.
  • Known severe hypersensitivity to Sorafenib or any component of the formulation.
  • Caution should be exercised with the concomitant use of other CYP3A4 inducers, such as rifampin, St. John's Wort, phenytoin, phenobarbital and dexamethasone.
  • Uncontrolled hypertension with a systolic blood pressure greater than 160 or a diastolic blood pressure greater than 100 despite treatment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00510289

Locations
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
Sponsors and Collaborators
Duke University
Bayer
Investigators
Principal Investigator: David A Rizzieri, MD Duke University
  More Information

Additional Information:
No publications provided

Responsible Party: Duke University
ClinicalTrials.gov Identifier: NCT00510289     History of Changes
Other Study ID Numbers: Pro00008151
Study First Received: July 30, 2007
Results First Received: October 30, 2013
Last Updated: December 20, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Duke University:
Sorafenib
Myelodysplastic Syndromes
MDS

Additional relevant MeSH terms:
Leukemia
Leukemia, Myelomonocytic, Chronic
Myelodysplastic Syndromes
Preleukemia
Neoplasms by Histologic Type
Neoplasms
Leukemia, Myeloid
Myelodysplastic-Myeloproliferative Diseases
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Sorafenib
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 26, 2014